Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors

Growth Factor ◽

Renal Cell ◽

Kinase Inhibitors ◽

Checkpoint Inhibitors ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal-cell carcinoma (RCC): Systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e16573 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e16573-e16573

Author(s):

Tobias Engel Ayer Botrel ◽

Luciano Paladini ◽

Otávio Clark ◽

Luciana Clark ◽

Bruna Pegoretti Rosa

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Growth Factor ◽

Renal Cell ◽

Kinase Inhibitors ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Position

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2012.11.006 ◽

2013 ◽

Vol 11 (1) ◽

pp. 1-4 ◽

Cited By ~ 5

Author(s):

Sumanta Kumar Pal ◽

Nicholas J. Vogelzang

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitors ◽

Mammalian Target Of Rapamycin ◽

Vascular Endothelial ◽

Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2011.02.012 ◽

2013 ◽

Vol 31 (4) ◽

pp. 493-498 ◽

Cited By ~ 28

Author(s):

Tomoaki Terakawa ◽

Hideaki Miyake ◽

Yuji Kusuda ◽

Masato Fujisawa

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Radical Nephrectomy ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Prognostic Predictor ◽

Everolimus in Patients with Metastatic Renal Cell Carcinoma Who Progress after Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: UK Results from the react Trial on Behalf of the UK React Investigators

Annals of Oncology ◽

10.1016/s0923-7534(20)33390-1 ◽

2012 ◽

Vol 23 ◽

pp. ix271-ix272

Author(s):

S. Chowdhury ◽

J. Larkin

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Renal Cell ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

The Uk ◽

Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

International Journal of Urology ◽

10.1111/iju.12423 ◽

2014 ◽

Vol 21 (7) ◽

pp. 741-741

Author(s):

Yoshihiro Wada

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Previously Treated ◽

Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.4580 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 4580-4580

Author(s):

Erin B. Bailey ◽

Srinivas Kiran Tantravahi ◽

Austin Poole ◽

Chesley E. Wells ◽

Julia A. Batten ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Renal Cell ◽

Kinase Inhibitors ◽

Vascular Endothelial ◽

Treatment Dose ◽

Hand Foot Syndrome ◽

Endothelial Growth Factor ◽

Dose Reductions

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Pathology & Oncology Research ◽

10.1007/s12253-017-0323-2 ◽

2017 ◽

Vol 25 (1) ◽

pp. 51-58 ◽

Cited By ~ 3

Author(s):

Heounjeong Go ◽

Mun Jung Kang ◽

Pil-Jong Kim ◽

Jae-Lyun Lee ◽

Ji Y. Park ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Vegfr Tyrosine Kinase Inhibitor

Single nucleotide polymorphisms of the vascular endothelial growth factor receptor - a promising biomarker in metastatic renal cell carcinoma

BJU International ◽

10.1111/bju.13617 ◽

2016 ◽

Vol 118 (6) ◽

pp. 847-848

Author(s):

Solomon L. Woldu ◽

Vitaly Margulis

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Single Nucleotide Polymorphisms ◽

Renal Cell ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Nucleotide Polymorphisms ◽

Single Nucleotide ◽

Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models

Neoplasia ◽

10.1593/neo.101162 ◽

2011 ◽

Vol 13 (1) ◽

pp. 49-59 ◽

Cited By ~ 13

Author(s):

Inga J. Duignan ◽

Erik Corcoran ◽

Anthony Pennello ◽

Mary Jane Plym ◽

Michael Amatulli ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Antibody Therapy ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors

Tumor Biology ◽

10.1007/s13277-015-4339-5 ◽

2015 ◽

Vol 37 (4) ◽

pp. 4919-4927 ◽

Cited By ~ 4

Author(s):

Inkeun Park ◽

Yong Mee Cho ◽

Jae-Lyun Lee ◽

Jin-Hee Ahn ◽

Dae-Ho Lee

Keyword(s):

Renal Cell Carcinoma ◽

Receptor Tyrosine Kinase Inhibitors

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Tissue Biomarker ◽